STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Perampanel

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled
- Not Controlled

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is not similar to any of the substances listed in the schedules to the CDSA.

Prepared by: _______________________________ Date: June 1, 2011

Zack Li

Verified by: _______________________________ Date: __________

Mark Kozlowski

Approved by: _______________________________ Date: __________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: Wissam Sader, OCS
Drug Status Report

Drug: Perampanel

Drug Name Status: Perampanel is the common name.

Chemical Name: 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1'H)-one

Chemical structure:

\[
\begin{align*}
&\begin{array}{c}
\text{Chemical structure:} \\
&\text{Pharmacological class / Application: Glutamate receptor antagonist}
\end{array}
\end{align*}
\]

International status:

US: Perampanel is not listed on the schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: Perampanel is an AMPA-type glutamate receptor currently undergoing clinical trials as a treatment for Parkinson’s Disease\(^1\). The substance is not listed in the CDSA and is not structurally similar to any of the other substances included in the Schedules to the CDSA.

Recommendation: Perampanel is not included in the Schedules to the CDSA and is not a controlled substance.

Date: June 1, 2011

---

\(^1\)Templeton, D. (2010). Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist following once- and multiple-daily dosage. Epilepsia \textbf{51}: 70-70